Processing

Please wait...

Settings

Settings

Goto Application

1. WO2001055316 - NUCLEIC ACIDS, PROTEINS, AND ANTIBODIES

Publication Number WO/2001/055316
Publication Date 02.08.2001
International Application No. PCT/US2001/001328
International Filing Date 17.01.2001
Chapter 2 Demand Filed 23.08.2001
IPC
A61K 38/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61K 48/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C07K 14/47 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
C07K 14/705 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
C07K 16/18 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
C12N 9/00 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
CPC
A01K 2217/05
AHUMAN NECESSITIES
01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
2217Genetically modified animals
05Animals comprising random inserted nucleic acids (transgenic)
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61K 48/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C07K 14/47
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
C07K 14/705
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
Applicants
  • HUMAN GENOME SCIENCES, INC. [US]/[US] (AllExceptUS)
  • ROSEN, Craig, A. [US]/[US] (UsOnly)
  • BARASH, Steven, C. [US]/[US] (UsOnly)
  • RUBEN, Steven, M. [US]/[US] (UsOnly)
Inventors
  • ROSEN, Craig, A.
  • BARASH, Steven, C.
  • RUBEN, Steven, M.
Agents
  • HOOVER, Kenley, K.
Priority Data
60/179,06531.01.2000US
60/180,62804.02.2000US
60/184,66424.02.2000US
60/186,35002.03.2000US
60/189,87416.03.2000US
60/190,07617.03.2000US
60/198,12318.04.2000US
60/205,51519.05.2000US
60/209,46707.06.2000US
60/214,88628.06.2000US
60/215,13530.06.2000US
60/216,64707.07.2000US
60/216,88007.07.2000US
60/217,48711.07.2000US
60/217,49611.07.2000US
60/218,29014.07.2000US
60/220,96326.07.2000US
60/220,96426.07.2000US
60/224,51814.08.2000US
60/224,51914.08.2000US
60/225,21314.08.2000US
60/225,21414.08.2000US
60/225,26614.08.2000US
60/225,26714.08.2000US
60/225,26814.08.2000US
60/225,27014.08.2000US
60/225,44714.08.2000US
60/225,75714.08.2000US
60/225,75814.08.2000US
60/225,75914.08.2000US
60/226,27918.08.2000US
60/226,68122.08.2000US
60/226,86822.08.2000US
60/227,00923.08.2000US
60/227,18222.08.2000US
60/228,92430.08.2000US
60/229,28701.09.2000US
60/229,34301.09.2000US
60/229,34401.09.2000US
60/229,34501.09.2000US
60/229,50905.09.2000US
60/229,51305.09.2000US
60/230,43706.09.2000US
60/230,43806.09.2000US
60/231,24208.09.2000US
60/231,24308.09.2000US
60/231,24408.09.2000US
60/231,41308.09.2000US
60/231,41408.09.2000US
60/231,96812.09.2000US
60/232,08008.09.2000US
60/232,08108.09.2000US
60/232,39714.09.2000US
60/232,39814.09.2000US
60/232,39914.09.2000US
60/232,40014.09.2000US
60/232,40114.09.2000US
60/233,06314.09.2000US
60/233,06414.09.2000US
60/233,06514.09.2000US
60/234,22321.09.2000US
60/234,27421.09.2000US
60/234,99725.09.2000US
60/234,99825.09.2000US
60/235,48426.09.2000US
60/235,83427.09.2000US
60/235,83627.09.2000US
60/236,32729.09.2000US
60/236,36729.09.2000US
60/236,36829.09.2000US
60/236,36929.09.2000US
60/236,37029.09.2000US
60/236,80202.10.2000US
60/237,03702.10.2000US
60/237,03802.10.2000US
60/237,03902.10.2000US
60/237,04002.10.2000US
60/239,93513.10.2000US
60/239,93713.10.2000US
60/240,96020.10.2000US
60/241,22120.10.2000US
60/241,78520.10.2000US
60/241,78620.10.2000US
60/241,78720.10.2000US
60/241,80820.10.2000US
60/241,80920.10.2000US
60/241,82620.10.2000US
60/244,61701.11.2000US
60/246,47408.11.2000US
60/246,47508.11.2000US
60/246,47608.11.2000US
60/246,47708.11.2000US
60/246,47808.11.2000US
60/246,52308.11.2000US
60/246,52408.11.2000US
60/246,52508.11.2000US
60/246,52608.11.2000US
60/246,52708.11.2000US
60/246,52808.11.2000US
60/246,53208.11.2000US
60/246,60908.11.2000US
60/246,61008.11.2000US
60/246,61108.11.2000US
60/246,61308.11.2000US
60/249,20717.11.2000US
60/249,20817.11.2000US
60/249,20917.11.2000US
60/249,21017.11.2000US
60/249,21117.11.2000US
60/249,21217.11.2000US
60/249,21317.11.2000US
60/249,21417.11.2000US
60/249,21517.11.2000US
60/249,21617.11.2000US
60/249,21717.11.2000US
60/249,21817.11.2000US
60/249,24417.11.2000US
60/249,24517.11.2000US
60/249,26417.11.2000US
60/249,26517.11.2000US
60/249,29717.11.2000US
60/249,29917.11.2000US
60/249,30017.11.2000US
60/250,16001.12.2000US
60/250,39101.12.2000US
60/251,03005.12.2000US
60/251,47906.12.2000US
60/251,85608.12.2000US
60/251,86808.12.2000US
60/251,86908.12.2000US
60/251,98805.12.2000US
60/251,98908.12.2000US
60/251,99008.12.2000US
60/254,09711.12.2000US
60/256,71905.12.2000US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) NUCLEIC ACIDS, PROTEINS, AND ANTIBODIES
(FR) ACIDES NUCLEIQUES, PROTEINES ET ANTICORPS
Abstract
(EN) The present invention relates to novel prostate cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as 'prostate cancer antigens', and the use of such prostate cancer antigens for detecting disorders of the prostate, particularly the presence of prostate cancer and prostate cancer metastases. More specifically, isolated prostate cancer associated nucleic acid molecules are provided encoding novel prostate cancer associated polypeptides. Novel prostate cancer polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human prostate cancer associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the prostate, including prostate cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.
(FR) L'invention concerne de nouveaux polynucléotides associés au cancer de la prostate et les polypeptides codés par ces polynucléotides désignés ici collectivement par 'antigènes du cancer de la prostate', ainsi que l'utilisation de tels antigènes du cancer de la prostate pour détecter des troubles de la prostate, notamment l'existence d'un cancer de la prostate et de métastases du cancer de la prostate. L'invention concerne plus spécifiquement des molécules d'acides nucléiques isolées associées au cancer de la prostate et codant pour de nouveaux polypeptides associés au cancer de la prostate. L'invention concerne aussi de nouveaux polypeptides du cancer de la prostate et des anticorps se liant à ces polypeptides, ainsi que des vecteurs, des cellules hôtes et des méthodes de recombinaison et de synthèse pour produire des polynucléotides ou des polypeptides humains associés au cancer de la prostate. L'invention concerne également des méthodes diagnostiques et thérapeutiques servant au diagnostic, au traitement, à la prévention ou à la prévision de troubles liés à la prostate, notamment du cancer de la prostate. L'invention concerne en outre des méthodes de sélection servant à identifier des agonistes et des antagonistes des polynucléotides et polypeptides selon l'invention. L'invention concerne enfin des méthodes ou des compositions servant à inhiber la production et la fonction des polypeptides selon l'invention.
Related patent documents
EP2001934818This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
Latest bibliographic data on file with the International Bureau